Respiratory News and Research

RSS

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

A new monoclonal antibody targets a particular region of the RBD on the SARS-CoV-2. This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities.

9 Apr 2021

How has the COVID-19 pandemic affected sleep patterns for many US citizens?

A team of scientists recently conducted an online survey to examine the changes in sleep duration among adult US citizens during the COVID-19 pandemic.

9 Apr 2021

Study finds no evidence of SARS-CoV2 transmission by breast milk

Some studies have reported the detection of SARS-CoV-2 RNA in breast milk from women who were recently infected with the virus. A new study explores the relationship between viral RNA and infectious virus to clarify the occurrence of vertical transmission through breast milk.

9 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

A new study shows the correlation between serum levels of antibodies to SARS-CoV-2 and levels in breast milk following the vaccination of lactating women with a vaccine based on mRNA technology.

9 Apr 2021

Study shows Urolithin A as a potent enhancer of muscle function in mice with muscular dystrophy

Progression of Duchenne Muscle Dystrophy (DMD) can be delayed in mice by supplementing their diets with Urolithin A, according to new results reported today.

9 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

Asymptomatic SARS-CoV-2 individuals with blood group AB at highest risk

Scientists worldwide are conducting extensive research to understand the nature of the virus, its transmission kinetics, etc. They have found a strong correlation between the ABO blood group and SARS-CoV-2 regarding its morbidity and mortality.

9 Apr 2021

Statins improve 28-day mortality in hospitalized COVID-19 patients

Now, researchers at Harvard Medical School showed that statin use reduced 28-day mortality in patients hospitalized with COVID-19. Both the new initiation of statins and continuing statin therapy reduced the risk of mortality.

8 Apr 2021

High SARS-CoV-2 attack rates linked to singing events

Now, a team of researchers from the Netherlands and Sweden demonstrates that airborne spread via infectious droplets or aerosols over longer distances of more than 1.5 meters due to singing is possible during singing events.

8 Apr 2021

More new SARS-CoV-2 variants are highly likely

In a recent report posted to the bioRxiv preprint server, researchers from the United Kingdom and Uganda reveal unique protein features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) relative to other representatives of Sarbecoviruses.

8 Apr 2021

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

New research in the USA and China. investigated how autoantibodies could mediate NETs during a COVID-19 infection. Extensive damage to the body from neutrophil extracellular traps (NETs) after infection may be contributing to thromboinflammation and the symptoms experienced by COVID-19 ‘long-haulers’.

8 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

A new preprint research paper posted to the bioRxiv server reports on the ability of a set of neutralizing mouse antibodies to protect mice against multiple lineages of SARS-CoV-2.

8 Apr 2021

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.

8 Apr 2021

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Mobility tracking using cell phone data showing greater movement of people is a strong predictor of increased rates of COVID-19, according to new data in CMAJ (Canadian Medical Association Journal)

8 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

Cross-border asthma study investigates hygiene hypothesis amid COVID-19 pandemic

A cross-border investigation of children's susceptibility to asthma and other childhood illnesses in the United States and Mexico is the focus of a new study led by researchers in the Asthma and Airway Disease Research Center at the University of Arizona Health Sciences.

8 Apr 2021

Respiratory News and Research

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

How has the COVID-19 pandemic affected sleep patterns for many US citizens?

Study finds no evidence of SARS-CoV2 transmission by breast milk

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Serum and breast milk SARS-CoV-2 antibodies correlated in vaccinated mothers

Study shows Urolithin A as a potent enhancer of muscle function in mice with muscular dystrophy

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Asymptomatic SARS-CoV-2 individuals with blood group AB at highest risk

Statins improve 28-day mortality in hospitalized COVID-19 patients

High SARS-CoV-2 attack rates linked to singing events

More new SARS-CoV-2 variants are highly likely

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Cross-border asthma study investigates hygiene hypothesis amid COVID-19 pandemic

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News